Two new successful trials in abatacept, APIPPRA and ARIAA, are the first to convincingly demonstrate the potential of a preventive approach to RA treatment.
The Prospect of Rheumatoid Arthritis Prevention
Rheumatoid arthritis (RA) is treatable, and for that, we should be grateful. But wouldn’t it be better if we could prevent it from even happening? Recent data from a study in China demonstrated some interesting results. Could an older type of diabetes medication be the answer we’ve been looking for? Background Preclinical studies have suggested…
3 AC&R Study Summaries: Frailty & Prefrailty in RA, Premature Mortality in Gout & Using Recruitment & Multidisciplinary Care Incentives to Improve Access
Frailty & Prefrailty in Patients with RA TNF-α inhibitors associated with higher infection risk By Namrata Singh, MD, MSCI, Katherine D. Wysham, MD, James S. Andrews, MD, & Una E. Makris, MD Why was this study done? Frailty and prefrailty are more common and occur at a younger age in patients with rheumatoid arthritis (RA)…
Can an App Reduce the Need for In-Person Visits?
Solomon et al. examined whether a mobile application (app) for patients with rheumatoid arthritis integrated in the electronic health record would be used by patients and rheumatologists.
Optimizing DMARD Use in Older Adults with Rheumatoid Arthritis
SAN DIEGO—Older adults with rheumatoid arthritis (RA) comprise two groups: those who have lived with diagnosed RA since an early age (young-onset RA) and those who have new-onset RA diagnosed at an older age (≥65 years), known as late-onset RA or, formerly, as elderly onset RA.1 Individuals with late-onset RA have more acute and systemic…
Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of a Difficult-to-Treat Disease
Difficult-to-treat rheumatoid arthritis (RA) is defined as the failure of two or more classes of biologic or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) to control active or progressive disease in patients with RA. Between 5 and 20% of patients with RA have difficult-to-treat RA.
The Risk of Cardiovascular Events in Patients with RA & More Explored in 3rd Plenary Session
SAN DIEGO—In one presentation at Plenary Session 3, ACR Convergence 2023, Beth Wallace, MD, MSc, a staff physician at the VA Ann Arbor Healthcare System, Michigan, and an assistant professor at the University of Michigan, Ann Arbor, shared important data on the relationship between time-dependent cumulative glucocorticoid exposure and major adverse cardiovascular events (MACE) in a cohort of veterans with rheumatoid arthritis (RA).
Get AMPed: Understanding RA Through the Accelerating Medicines Partnership
SAN DIEGO—The Accelerating Medicines Partnership (AMP) is a public-private collaboration involving the National Institutes of Health (NIH), the U.S. Food & Drug Administration (FDA), multiple biopharmaceutical and life science companies, and nonprofit organizations, all joined together with the goal of transforming diagnosis and treatments for a multitude of diseases. One such condition that has been…
What’s New in RA Research?
Dr. Aletaha discussed several studies of interventions in pre-RA, including SAVE, STIVEA, PROMPT, PRAIRI, TREAT EARLIER and STOP-RA.
All That Is Old—& New: Treatment Implications for Rheumatoid Arthritis
EULAR 2023 (MILAN)—Over the past several years, a plethora of new treatments for patients with rheumatoid arthritis (RA) has emerged, while older treatments still play a large role in therapy for many patients. At the EULAR 2023 session titled Rheumatoid Arthritis: New Small Molecules and Old DMARDs, several speakers presented abstracts comparing different treatment effects…